Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
N05 CH01
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Hetlioz
|
| gptkbp:casnumber |
856681-05-5
|
| gptkbp:class |
hypnotics and sedatives
|
| gptkbp:clinical_trial |
NCT01620258
NCT01620271 NCT01620284 |
| gptkbp:clinical_use |
chronic insomnia
|
| gptkbp:condition |
blindness
sleep-wake disorders circadian rhythm sleep disorders |
| gptkbp:contraindication |
hypersensitivity to tasimelteon
|
| gptkbp:dosage_form |
20 mg
|
| gptkbp:drug_interactions |
CYP2 C19 inhibitors
CYP3 A4 inducers CYP1 A2 inhibitors |
| gptkbp:duration |
long-term
|
| gptkbp:effective_date |
January 2014
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hetlioz
|
| gptkbp:indication |
sleep disorders
|
| gptkbp:ingredients |
tasimelteon
|
| gptkbp:lifespan |
1.5 hours
|
| gptkbp:manufacturer |
Vanda Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:metabolism |
liver
|
| gptkbp:monitors |
0 A0 D1 B5 F9 H
|
| gptkbp:patient_population |
blind individuals
|
| gptkbp:pharmacokinetics |
oral bioavailability
melatonin receptor agonist |
| gptkbp:price |
varies by pharmacy
|
| gptkbp:provides_guidance_on |
recommended for Non-24-Hour Sleep-Wake Disorder
|
| gptkbp:requires |
available online
|
| gptkbp:research |
Impact on quality of life
Effects on sleep architecture Comparison with placebo Efficacy in Non-24-Hour Sleep-Wake Disorder Safety in long-term use |
| gptkbp:research_areas |
circadian rhythm disorders
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety |
Category C
|
| gptkbp:side_effect |
dizziness
fatigue headache nausea somnolence |
| gptkbp:structure |
C17 H19 N3 O
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
treatment of Non-24-Hour Sleep-Wake Disorder
|